- Home
- IBIO vs NXTC Comparison
IBIO vs NXTC Comparison
Compare IBIO & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- NXTC
- Stock Information
- Founded
- IBIO 2008
- NXTC 2015
- Country
- IBIO United States
- NXTC United States
- Employees
- IBIO N/A
- NXTC N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- NXTC Health Care
- Exchange
- IBIO Nasdaq
- NXTC Nasdaq
- Market Cap
- IBIO 11.9M
- NXTC 13.0M
- IPO Year
- IBIO N/A
- NXTC 2019
- Fundamental
- Price
- IBIO $0.93
- NXTC $5.40
- Analyst Decision
- IBIO Strong Buy
- NXTC Strong Buy
- Analyst Count
- IBIO 2
- NXTC 2
- Target Price
- IBIO $5.50
- NXTC $25.50
- AVG Volume (30 Days)
- IBIO 2.1M
- NXTC 16.9K
- Earning Date
- IBIO 11-11-2025
- NXTC 11-06-2025
- Dividend Yield
- IBIO N/A
- NXTC N/A
- EPS Growth
- IBIO N/A
- NXTC N/A
- EPS
- IBIO N/A
- NXTC N/A
- Revenue
- IBIO $400,000.00
- NXTC N/A
- Revenue This Year
- IBIO N/A
- NXTC N/A
- Revenue Next Year
- IBIO N/A
- NXTC N/A
- P/E Ratio
- IBIO N/A
- NXTC N/A
- Revenue Growth
- IBIO 77.78
- NXTC N/A
- 52 Week Low
- IBIO $0.56
- NXTC $2.69
- 52 Week High
- IBIO $6.89
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- IBIO 64.71
- NXTC 57.83
- Support Level
- IBIO $0.77
- NXTC $4.77
- Resistance Level
- IBIO $0.97
- NXTC $5.15
- Average True Range (ATR)
- IBIO 0.07
- NXTC 0.22
- MACD
- IBIO 0.01
- NXTC 0.05
- Stochastic Oscillator
- IBIO 82.62
- NXTC 86.90
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.